An interventional study of IPT-CPET in Immune Thrombocytopenic Purpura, sponsored by University Hospital, Bordeaux. Not yet recruiting at 5 sites in France. Open to participants aged 8 Years to 25 Years. Per ClinicalTrials.gov, last updated 2025-12-30.
Sponsored by University Hospital, Bordeaux · Not applicable, Interventional, and Other
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 12 studies in Purpura, Thrombocytopenic, Idiopathic by University Hospital, Bordeaux — 5 open to participants now, 5 under way, none of them phase 3. Purpura, Thrombocytopenic, Idiopathic · University Hospital, Bordeaux.
Among the 12 studies in Purpura, Thrombocytopenic, Idiopathic by University Hospital, Bordeaux, this one is the only one that started in 2025, is one of 4 with no phase, and was the 11th registered.
505 studies on the registry are indexed under Purpura, Thrombocytopenic, Idiopathic; 160 are open to participants now.
Browse Purpura, Thrombocytopenic, Idiopathic studies →5 of the 12 studies in Purpura, Thrombocytopenic, Idiopathic by University Hospital, Bordeaux are open now, in 1 country. Recruiting first, the newest first:
University Hospital, Bordeaux · Sites in France
Ages 18+
University Hospital, Bordeaux · Sites in France
Ages 18+
University Hospital, Bordeaux · Sites in France
Ages up to 17
University Hospital, Bordeaux · Sites in France
Ages 1–18 · Healthy volunteers
By country, each count listing its studies:
Of the 104 Purpura, Thrombocytopenic, Idiopathic studies recruiting now, 49 (47%) set no upper age limit and 43 (41%) stop at 75 or younger; 27 take children under 18; 4 take healthy volunteers.
This study: 8 Years to 25 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
12 studies; the count open now beside each. This study's row is marked.
First in 2007; this study’s year is marked. 1 started in 2025.
This study's planned enrollment of 53 is close to the median of 58 across 378 interventional studies indexed under Purpura, Thrombocytopenic, Idiopathic.
Median enrollment 70 across the 5 interventional studies, 158 across the 7 observational. Of the 7 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
University Hospital, Bordeaux is the lead sponsor of 807 studies on the registry; 198 are open to participants now.
2 of the studies in Purpura, Thrombocytopenic, Idiopathic by University Hospital, Bordeaux that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07310342University Hospital, BordeauxPhysical Fitness of Children, Adolescents and Young Adults With Immune Thrombocytopenic Purpura | 2026-12-15 |
| NCT04005638University Hospital, BordeauxBiological Bank for the Patients Followed in a Constitutive Reference Center for Autoimmune Cytopenia | 2027-01 |
Add all 2 to your calendar (.ics) → With an account.
Among the 12 studies in Purpura, Thrombocytopenic, Idiopathic by University Hospital, Bordeaux, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Patients with chronic immune thrombocytopenic purpura (ITP) live with an anxiety-inducing risk of haemorrhage that is unpredictable over several months or years.
They also rate fatigue as one of the most frequent (48%) and most severe (73%) disabling symptoms, which contributes to a reduced quality of life [Cooper, 2021].
In this autoimmune disease targeting platelets, fatigue could be mediated by platelet and immunological abnormalities, and/or promoted by psychobehavioural determinants that are poorly understood in this chronic disease.
Since 1980, the World Health Organisation has stated that functional capacity assessments best reflect the impact of chronic diseases on quality of life, with fatigue playing an important role. The association between fatigue and aerobic physical capacity, determined by maximum oxygen consumption (VO2max), has been demonstrated in several pathologies. It is often associated with the vicious circle of deconditioning, where the impact of the disease on cardiac, muscular and respiratory functions is intertwined with inactive or sedentary behaviours.
At the end of this vicious circle, adults have been shown to have an increased cardiovascular risk and a high prevalence of anxiety and depression syndromes.
VO2max measured by cardiopulmonary exercise testing (CPET) is increasingly used in monitoring, as recommended by the French Society of Cardiology [Marcadet, 2018;Marcadet, 2019]. Our team (Amedro et al.) has set up a research programme on aerobic physical capacity and deconditioning to exercise in chronic childhood diseases and has just published the reference values for exercise tests in healthy paediatric populations, enabling the interpretation of VO2max results in sick children [Gavotto,2023].
However, it has been demonstrated that the VO₂ plateau is not predominantly reached in healthy adults and is rarely reached (\<25%) in healthy children. [Armstrong, 1996 ; Åstrand, 1952 ; Rowland, 1992].
Thus, the highest oxygen consumption measurement (VO2pic) is often used instead of VO2max to define aerobic capacity. We will therefore use the concepts of VO2max and VO2pic in this study.
The first population studied by our team was children with congenital heart disease, who showed a significant reduction in their VO2max [Amedro, 2018]. Based on these results, a functional rehabilitation programme (QUALIREHAB) was set up and evaluated in a randomised controlled clinical trial [Amedro, 2019] . The data demonstrate its positive impact not only on VO2max, but also on quality of life. Aerobic physical capacity was assessed in chronic paediatric diseases without direct cardiac involvement.
We have also shown that VO2max declines more rapidly over time in children, adolescents and young adults who have survived childhood cancer [Gavotto, 2023] or in children with asthma [Moreau, 2023].
To date, no prospective controlled studies have reported on the level of aerobic physical capacity in children, adolescents and young adults with cITP.
We therefore hypothesise that fatigue in patients monitored for cITP could be correlated with a decrease in their aerobic physical capacity, causing these patients to enter a 'vicious cycle of deconditioning'. If this hypothesis is verified, an exercise rehabilitation programme could have a positive impact on quality of life, physical health and mental health
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Presence of at least one to performing an exercise test
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Children, adolescents and young adults aged 8 to 25 followed for ITPc (N=53)
Other: IPT-CPET
Patients with ITP will undergo standard care, medical examination, cardiopulmonary exercise test (CPET), muscular strength and physical activity tests, and validated questionnaires of health-related and disease-related quality of life, mental health, and physical activity
VO2max measured by exercise testing
Values will be standardised using paediatric reference values.
Time frame: Day 1
First ventilatory threshold (SV1)
as a percentage of theoretical VO2max
Time frame: Day 1
Ventilatory efficiency
VE/VCO2 slope
Time frame: Day 1
Maximal power
Time frame: Day 1
Oxygen pulse
Time frame: Day 1
Maximum heart rate
Time frame: Day 1
Respiratory exchange ratio
Time frame: Day 1
Respiratory reserve
Time frame: Day 1
Health-related quality of life
PedsQL®
Time frame: Day 1
Disease-specific quality of life
Kids ITP Tools
Time frame: Day 1
Muscular force evaluation
Handgrip®
Time frame: Day 1
Muscular force evaluation
standing long jump
Time frame: Day 1
Physical activity evaluation
level of physical activity evaluated using an accelerometer
Time frame: Between Day 1 and Day 7
Physical activity evaluation
* Children and Adolescents Physical Activity and Sedentary Questionnaire * International Physical Activity Questionnaire
Time frame: Day 1
Mental health evaluation
* Strenghts and difficulties questionnaire * Adolescent Depression Rating Scale * Patient Health Questionnaire (PHQ-9)
Time frame: Day 1
Fatigue evaluation
Fat-PTI questionnaire
Time frame: Day 1
Start is estimated for Dec 2025; primary completion for Dec 2026, 12 months later.
How these figures are worked out, and which studies are left out of them.
This study is not yet recruiting, as verified in Dec 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Purpura, Thrombocytopenic, Idiopathic →
University Hospital, Bordeaux →